No-Bottle67
liked
buy yesterday sell todus only wont kena screwed. buy this morning already get trapped. wait for 5 more days may be.
my swing between RM350,000 is like really crazy. thanks to $ECOWLD-WB (ECO WORLD DEVELOPMENT GROUP BERHAD) (8206WB.MY)$ $TENAGA (5347.MY)$ $SIMEPROP (5288.MY)$
follow me to see me die. i am the useless sugarbabe just know kena hantam!
$YTLPOWR (6742.MY)$
$YTL (4677.MY)$
my swing between RM350,000 is like really crazy. thanks to $ECOWLD-WB (ECO WORLD DEVELOPMENT GROUP BERHAD) (8206WB.MY)$ $TENAGA (5347.MY)$ $SIMEPROP (5288.MY)$
follow me to see me die. i am the useless sugarbabe just know kena hantam!
$YTLPOWR (6742.MY)$
$YTL (4677.MY)$


24
10
2
No-Bottle67
liked
Recently, $Tesla (TSLA.US)$ (NASDAQ: TSLA) has become the market focus, and its stock price has experienced significant volatility, mainly due to Musk's (Elon Musk) political involvement、Variables in electric vehicle market demand. and Competition pressure is intensifying. Due to multiple factors, investors cannot help but start pondering whether Tesla's growth story still holds. Or should one remain cautious regarding this leading electric vehicle company? This article will analyze the key factors affecting Tesla's stock price variations from the perspective of the future investment opportunities. US stocks 101 Perspective will delve into the key factors affecting Tesla's stock price fluctuations and explore future investment opportunities.
Tesla Q1 performance: Revenue is solid, but financial forecasts raise market concerns.
Tesla's latest Earnings Reports indicate that the company's revenue in Q1 2024 reached 25.4 billion USD, a growth compared to the same period last year. 7%, but still lower than market expectations. Adjusted Earnings Per Share (EPS) is 0.78 USD, compared to the same period last year. 1.19 USD decline 34%This reflects the impact of rising costs and compressed gross margins. Additionally, the company has provided the full-year earnings forecast for 2024 which is below Wall Street expectations, causing market sentiment to become cautious.
Despite robust revenue, Tesla's gross margin has fallen to 17.6%., compared to the same period last year. 21.4% There is a significant decline, which is due to Price war the impact on the company's profits. Increased competition in the China market, companies like BYD continue to lower electric vehicle prices, and Tesla in order to...
Tesla Q1 performance: Revenue is solid, but financial forecasts raise market concerns.
Tesla's latest Earnings Reports indicate that the company's revenue in Q1 2024 reached 25.4 billion USD, a growth compared to the same period last year. 7%, but still lower than market expectations. Adjusted Earnings Per Share (EPS) is 0.78 USD, compared to the same period last year. 1.19 USD decline 34%This reflects the impact of rising costs and compressed gross margins. Additionally, the company has provided the full-year earnings forecast for 2024 which is below Wall Street expectations, causing market sentiment to become cautious.
Despite robust revenue, Tesla's gross margin has fallen to 17.6%., compared to the same period last year. 21.4% There is a significant decline, which is due to Price war the impact on the company's profits. Increased competition in the China market, companies like BYD continue to lower electric vehicle prices, and Tesla in order to...
Translated

4
No-Bottle67
liked
No-Bottle67
liked
When top-performing funds go on a buying spree, savvy investors pay attention. These stock moves aren’t just numbers on a spreadsheet, they’re signals of confidence in specific sectors that could dictate the market’s next big winners. For ETF strategists and investors alike, tracking these shifts can reveal emerging opportunities. But not every stock that funds scoop up is destined for long-term success. A disciplined, strategic approach i...

6
No-Bottle67
liked
$Xilio Therapeutics (XLO.US)$
The clinical data emerging from Xilio's pipeline demonstrates promising therapeutic potential. The vilastobart results in microsatellite stable colorectal cancer represent a meaningful advance in addressing an immunologically "cold" tumor type that has historically resisted immunotherapy approaches. A 27% objective response rate in patients without liver metastases indicates significant activity, especially when accompanied by decreases in t...
The clinical data emerging from Xilio's pipeline demonstrates promising therapeutic potential. The vilastobart results in microsatellite stable colorectal cancer represent a meaningful advance in addressing an immunologically "cold" tumor type that has historically resisted immunotherapy approaches. A 27% objective response rate in patients without liver metastases indicates significant activity, especially when accompanied by decreases in t...
6